ASCO may have been virtual this year because of the COVID-19 pandemic, but there were still some show-stopping moments, reports Richard Staines. This time of year oncologists from
The World Health Organization has restarted its trial of COVID-19 drug hydroxychloroquine, the malaria drug favoured by president Donald Trump, after a temporary halt because of safety conc
An influential analyst has upped his previously cautious assessment of the sales potential of Gilead’s COVID-19 drug remdesivir, saying sales could reach $7.7 billion in 2022.
Eli Lilly has started dosing patients in the world's first trial for a medicine specifically designed to attack SARS-CoV-2, the virus that causes COVID-19.
Like all UK pharma GMs working during the COVID-19 pandemic, Teva’s Kim Innes has found herself leading her company through an unprecedented crisis in one of the worst-hit countries in the